Issues in the design of the fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation

Clinical Infectious Diseases

Volumn 39, Issue SUPPL. 4, 2004, Pages

  Marr, Kieren A ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; PLACEBO;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIFUNGAL PROPHYLAXIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG EFFICACY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION PREVENTION; MORTALITY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 12844256352     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421952     Document Type: Article

References (6)

1. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326:845-51.
2. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171: 1545-52.
3. Ascioglu A, Rex J, DePauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
4. Marr K, Seidel K, Slavin M, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-61.
5. Shih W. Problems in dealing with missing data and informative censoring in clinical trials. Current Control Trials Cardiovascular Medicine 2002; 3:4.
6. Marr KA. Empirical antifungal therapy - new options, new tradeoffs. N Engl J Med 2002; 346:278-80.